Etonogestrel


Concise Prescribing Info
Indications/Uses
Contraception.
Dosage/Direction for Use
Adult : Vag Per vag ring delivers etonorgestrel 120 mcg and ethinylestradiol 15 mcg daily. Insert 1 ring into the vagina on the 1st day of menstruation. Leave the ring in place for 3 wk, then allow for 1 wk break. Insert a new ring 1 wk after removal of the previous ring. Subdermal Per implant contains 68 mg of etonorgestrel: Insert 1 implant during the 1st 5 days of menstruation. Remove no later than 3 yr after date of insertion.
Dosage Details
Subdermal
Contraception
Adult: Each implant contains 68 mg of etonogestrel: 1 implant is inserted during the 1st 5 days of the menstrual cycle; remove within 3 yr of insertion.

Vaginal
Contraception
Adult: Each vaginal ring delivers 120 mcg of etonorgestrel and 15 mcg of ethinylestradiol daily. Insert one ring into the vagina on the 1st day of menstruation. Leave the ring in place continuously for 3 wk. Remove it after 3 wk for the 1 wk break during which breakthrough bleeding will occur. Insert a new ring 1 wk after removal of the previous ring.
Contraindications
Pregnancy, undiagnosed vag bleeding, severe arterial disease; liver adenoma; active liver disease; current or history of thromboembolic disorders; porphyria; after evacuation of hydatidiform mole; history of breast cancer.
Special Precautions
Heart disease, sex-steroid dependent cancer, history of ectopic pregnancy, malabsorption syndromes, functional ovarian cysts, recurrent cholestatic jaundice, history of jaundice in pregnancy; history of pruritus during pregnancy or of deterioration of otosclerosis; disturbances of lipid metabolism; history of CV or renal impairment, DM, asthma, epilepsy, migraine, depression; lactation. May develop bleeding irregularities.
Adverse Reactions
Menstrual irregularities; nausea, vomiting, headache, dizziness, breast discomfort, gynaecomastia, depression, skin disorders, disturbance of appetite, wt changes, fluid retention, oedema, changes in libido, cholestatic jaundice, hair loss or hirsutism.
Drug Interactions
Reduced efficacy with hepatic enzyme-inducing drugs; aminoglutethimide. May inhibit ciclosporin metabolism. Changes in efficacy and safety of treatment when used in combination with protease inhibitors.
Lab Interference
May affect thyroxine and sex hormone blood globulin test results during the initial phase of treatment.
Action
Description: Etonogestrel is the active metabolite of desogestrel. It prevents pregnancy by suppressing ovulation, increasing viscosity of cervical mucous and inhibiting endometrial proliferation.
Pharmacokinetics:
Distribution: Highly bound to plasma proteins. Distributed into breast milk.
Metabolism: Metabolised by CYP3A4.
Excretion: Urine and faeces. Elimination half-life: About 25-30 hr.
Storage
Subdermal:
Store between 15-30°C.
Vaginal:
Store at 2-8°C prior to dispensing. May store at 25°C for up to 4 mths after dispensing.
Disclaimer: This information is independently developed by MIMS based on Etonogestrel from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Implanon/Implanon NXT
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in